Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Chuntao Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9954-8409; OpenAlex author ID A5004073260. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 4 papers · 2026: 6 papers

Papers 24

  1. Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Co-author DOI 10.1038/s41392-026-02641-4↗
  2. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  3. Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps. Co-author DOI 10.1158/0008-5472.can-26-0151↗
  4. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-0323↗
  5. Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: … Co-author DOI 10.20892/j.issn.2095-3941.2025.0848↗
  6. TNM stage I pancreatic ductal adenocarcinoma patients without pathological risk may drive limited benefit from adjuvant chemotherapy. Last author DOI 10.3389/fmed.2026.1914610↗
  7. Prognostic Significance of C-Reactive Protein or Prealbumin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2024.12.047↗
  8. Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling. Co-author DOI 10.1136/gutjnl-2024-333638↗
  9. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4↗
  10. Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing p… Co-author DOI 10.20892/j.issn.2095-3941.2024.0287↗
  11. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Co-author DOI 10.1016/j.surg.2024.07.047↗
  12. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective… Co-author DOI 10.1097/js9.0000000000000425↗
  13. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  14. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study. Co-author DOI 10.3389/fonc.2023.1276037↗
  15. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Co-author DOI 10.1038/s41416-022-01927-y↗
  16. Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.841819↗
  17. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. Co-author DOI 10.1002/jcsm.12692↗
  18. PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.021↗
  19. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2021.698302↗
  20. KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target. Co-author DOI 10.21037/atm-20-1970↗
  21. Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.33767↗
  22. Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer. Co-author DOI 10.3390/ijms18040622↗
  23. SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. Co-author DOI 10.1371/journal.pone.0121338↗
  24. CypA, a gene downstream of HIF-1α, promotes the development of PDAC. Co-author DOI 10.1371/journal.pone.0092824↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 16 shared papers, 2014–2026 · strength 2.60
  2. Tiansuo Zhao · 16 shared papers, 2014–2026 · strength 2.44
  3. Xiuchao Wang · 13 shared papers, 2014–2026 · strength 1.77
  4. Yuexiang Liang · 4 shared papers, 2024–2026 · strength 0.97
  5. Song Gao · 8 shared papers, 2014–2026 · strength 0.97
  6. Haorui Li · 4 shared papers, 2023–2025 · strength 0.90
  7. Xugang Sun · 4 shared papers, 2021–2025 · strength 0.74
  8. Rui Liu · 3 shared papers, 2025–2026 · strength 0.71
  9. Yongjie Xie · 4 shared papers, 2021–2026 · strength 0.70
  10. Tianxing Zhou · 3 shared papers, 2023–2026 · strength 0.60
  11. Shengyu Yang · 4 shared papers, 2021–2025 · strength 0.59
  12. Chongbiao Huang · 4 shared papers, 2021–2023 · strength 0.52
  13. Wenrun Cai · 3 shared papers, 2021–2025 · strength 0.44
  14. Shangheng Shi · 2 shared papers, 2026 · strength 0.44
  15. Jun Yu · 2 shared papers, 2026 · strength 0.42
  16. Shengnan Li · 3 shared papers, 2020–2022 · strength 0.41
  17. Jing Liu · 3 shared papers, 2021–2023 · strength 0.38
  18. Zhihua Li · 2 shared papers, 2025–2026 · strength 0.38
  19. Liangliang Wu · 2 shared papers, 2021–2026 · strength 0.37
  20. Shaofei Chang · 2 shared papers, 2023–2024 · strength 0.36
  21. Yiping Zou · 2 shared papers, 2023–2024 · strength 0.35
  22. Danqi Fu · 2 shared papers, 2023–2025 · strength 0.34
  23. Li Zhifei · 1 shared paper, 2026 · strength 0.33
  24. Xiaofan Guo · 2 shared papers, 2020–2023 · strength 0.30
  25. Xingyun Chen · 1 shared paper, 2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.